[Federal Register Volume 68, Number 131 (Wednesday, July 9, 2003)]
[Notices]
[Pages 40961-40965]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-17304]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 04009]


Viral Hepatitis Integration and Intervention Projects; Notice of 
Availability of Funds

    Application Deadline: October 7, 2003.

A. Authority and Catalog of Federal Domestic Assistance Number

    This program is authorized under section 301(a) and 317(k)(1) and 
317(k)(2) of the Public Health Service Act, (42 U.S.C. 241(k) and 
247b(k)(1) and 247(k)(2)), as amended. The Catalog of Federal Domestic 
Assistance number is 93.283.

B. Purpose

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 2004 funds for a cooperative agreement 
program for Viral Hepatitis Integration and Intervention Projects. This 
program addresses the ``Healthy People 2010'' focus area of 
Immunization and Infectious Diseases.
    The purpose of this program is to (1) improve the delivery of 
existing viral hepatitis prevention services in programs known to serve 
adults and adolescents at high risk for infection (e.g. Sexually 
Transmitted Disease (STD) clinics, Human Immunodeficiency Virus (HIV) 
counseling and testing sites, health care programs serving correctional 
facilities, primary health care settings, substance abuse prevention or 
treatment centers); (2) evaluate the effectiveness of different 
strategies to deliver recommended hepatitis preventive services (e.g. 
vaccination, testing and counseling, receipt of test results, and 
medical and other appropriate services for infected persons); (3) 
evaluate the impact of integration of viral hepatitis prevention 
services on existing prevention services (e.g., STD or HIV counseling 
and testing); (4) to conduct research to identify, develop and evaluate 
specific programmatic interventions and approaches to achieve 
successful integration of recommended preventive services and increase 
levels of coverage for these services; and (5) to produce materials 
that convey to other public health programs the lessons learned with 
respect to integration of viral hepatitis prevention activities into 
existing public health and clinical care programs.
    Recommendations for prevention and control of hepatitis A virus 
(HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV) among 
adults and adolescents at high risk of infection have been published by 
CDC (references 1-6, Appendix II, as posted with this announcement on 
the CDC web site). The primary goals of these recommendations are to 
decrease the incidence of acute viral hepatitis infections and to 
decrease the risk of complications from chronic infection with HBV or 
HCV among populations known to be at high risk for infection. Despite 
effective vaccines to prevent both HAV and HBV infections, and known 
behavioral changes necessary to prevent infection with HCV and the 
serious consequences of chronic HBV or HCV infection, new infections 
and adverse outcomes of chronic infection continue to occur among high 
risk adults and adolescents.
    Measurable outcomes of the program will be in alignment with one or 
more of the following performance goals for the National Center for 
Infectious Diseases (NCID): Protect Americans from Infectious Diseases; 
National Immunization Program (NIP): Reduce the number of indigenous 
cases of vaccine preventable diseases; and National Center for HIV, 
STD, and Tuberculosis (TB) Prevention (NCHSTP):
    Increase the proportion of HIV-infected people who are linked to 
appropriate prevention, care, and treatment services and strengthen the 
capacity nationwide to monitor the epidemic, develop and implement 
effective HIV prevention interventions and evaluate prevention 
programs.

C. Eligible Applicants

    Assistance will be provided only to the health departments of 
States or their bona fide agents and territories, including the 
District of Columbia, the Commonwealth of Puerto Rico, the Virgin 
Islands, the Commonwealth of the Northern Mariana Islands, American 
Samoa, Guam, the Federated States of Micronesia, the Republic of the 
Marshall Islands, the Republic of Palau, and federally recognized 
Indian tribal governments and political subdivisions of states (in 
consultation with States).

[[Page 40962]]

    This limited eligibility is due to the requirement that viral 
hepatitis services be integrated with existing state or local public 
health programs.
    State or local health departments are encouraged to partner with 
academic institutions in developing proposals for this announcement.

    Note: Title 2 of the United States Code section 1611 states that 
an organization described in section 501(c)(4) of the Internal 
Revenue Code that engages in lobbying activities is not eligible to 
receive Federal funds constituting an award, grant or loan.

D. Funding

Availability of Funds

    Approximately $2,900,000 is available in FY 2004 to fund 
approximately seven awards. It is expected that the average award will 
be $400,000 ranging from $300,000 to $500,000. It is expected that the 
awards will begin on or about January, 1, 2004, and will be made for a 
12-month budget period with a project period of up to five years. 
Funding estimates may change.
    Continuation awards within an approved project period will be made 
on the basis of satisfactory progress as evidenced by required reports 
and the availability of funds.

Use of Funds

    Cooperative agreement funds may be used to support personnel, 
purchase supplies, services, and travel directly related to program 
activities and consistent with the scope of the cooperative agreement. 
Funds under this program announcement may not be used to provide direct 
patient treatment services. Supplies may include, but are not limited 
to those for laboratory testing and hepatitis A and B vaccine for 
adults (any adolescents included in the projects may be eligible for 
free vaccine under the Vaccines for Children program), although other 
sources of funding for these essential supplies need to be sought. 
Computers and related technologic needs should be requested under 
supplies, not equipment, if less than $25,000. Consultants and sub-
contracts (e.g., with academic or other institutions) may be requested 
as appropriate. Federal funds awarded under this program announcement 
may not be used to supplant State or local funds.

Recipient Financial Participation

    Matching Funds are not required for this program.

Funding Preferences

    Preference will be given to programs that currently deliver viral 
hepatitis prevention services (e.g., hepatitis A and or hepatitis B 
vaccination services, hepatitis C counseling, testing, medical referral 
or case management for HCV positive persons) through an existing 
program serving adults (may also serve adolescents) at high risk for 
infection with hepatitis viruses, and are seeking to evaluate or 
improve these services. Such existing programs include, but are not 
limited to STD Clinics, HIV/AIDS counseling/testing sites, correctional 
health care settings, substance abuse treatment programs accessing and 
providing services to injection drug users (IDUs), and primary care 
health settings that are known to serve high risk populations.
    Preference will be given to programs that are able to determine the 
proportion of clients in their selected health/prevention delivery 
service setting who have known risk factors for infection with HBV, 
HCV, HAV or HIV (e.g., percent of clients served who are IDUs), and the 
proportion of clients who accept and receive recommended disease-
specific prevention services (e.g., percent of IDUs who receive 1st, 
2nd,and 3rd doses of hepatitis B vaccine or are tested for HCV 
infection, receive results, and, if HCV positive, undergo medical 
evaluation or other recommended services such as drug treatment if 
appropriate).
    Preference will be given to ensure a diversity of settings for 
delivery and evaluation of integrated prevention services. Applicants 
should specify one specific type of setting in which to concentrate 
efforts to improve and evaluate delivery of recommended services.

E. Program Requirements

    In conducting activities to achieve the purpose of this program, 
the recipient will be responsible for the activities listed under 1. 
Recipient Activities, and CDC will be responsible for the activities 
listed under 2. CDC Activities.
    1. Recipient Activities:
    a. Develop and implement a plan to improve the delivery of 
recommended viral hepatitis prevention services in an existing public 
health or primary care setting that serves known high risk adults and/
or adolescent populations, as appropriate for the particular setting 
proposed. References for current recommendations and integration 
experiences are included in Appendix II (as posted with this 
announcement on the CDC website). Core viral hepatitis prevention 
services should include:
    (1) Assessment of risk factors for viral hepatitis among all 
clients.
    (2) Performing appropriate testing of persons for HCV and HBV 
infection and appropriate pre-vaccination testing for immunity to HBV 
and/or HAV infection.
    (3) Client-centered viral hepatitis prevention counseling.
    (4) Hepatitis B vaccine for persons in appropriate risk groups 
(e.g., persons at risk of sexual transmission, including STD clients 
and men who have sex with men [MSM]; incarcerated persons; IDUs; and 
sex and household contacts of persons with chronic HBV infection).
    (5) Hepatitis A vaccine to persons in appropriate risk groups (e.g, 
MSM, illegal drug users).
    (6) Delivery of primary prevention services for anti-HCV positive 
and HBsAg-positive persons, including: (a) Counseling on how to prevent 
transmission to others, (b) identification of partners (sex and/or 
needle-sharing) for counseling and referral services, if appropriate, 
and (c) providing hepatitis B vaccine for at-risk (sex or needle-
sharing) partners and household contacts of HBsAg-positive persons.
    (7) Either directly or by referral, provide appropriate follow-up 
services to persons found to be anti-HCV or Hepatitis B Surface Antigen 
(HBsAg) positive, including: (a) Alcohol and drug counseling and/or 
treatment, and (b) medical evaluation for chronic liver disease and 
possible treatment, including assistance in accessing medical care.
    b.Monitor and evaluate prevention activities and intervention 
strategies, including:
    (1) Develop and provide a written plan to assess the success of 
strategies to improve hepatitis prevention service delivery (measuring 
both process and outcome components).
    (2) Implement the evaluation plan, including appropriate data 
collection and analysis, interpretation, and cost-effectiveness 
analyses. Of particular interest is to determine rates (at baseline and 
following intervention efforts) for services offered and accepted among 
clients, including:
    (a) HIV and HCV testing among clients recommended for testing.
    (b) Receipt of test results (STD, HIV, hepatitis).
    (c) HIV positives identified, HCV positives identified, co-
infections identified (or persons confirmed negative for one disease or 
both);
    (d) New and chronic infections with other STDs (e.g., syphilis, 
herpes) identified.
    (e) Follow up (which may be provided directly or by referral) for 
persons infected with HIV or HCV (e.g., appropriate evaluation and 
treatment for HIV disease, medical evaluation in HCV-positive persons, 
substance abuse

[[Page 40963]]

treatment when indicated, or other appropriate services; and outcome(s) 
of referral and follow up.
    (f) Dose-specific hepatitis A and hepatitis B vaccination coverage 
for persons for whom vaccine is recommended.
    c. Provide staff training regarding viral hepatitis prevention and 
control, including specialty training required to implement specific 
activities of the program.
    d. Participate in at least two national meetings (CDC, or Division 
of Viral Hepatitis (DVH), NCID-sponsored, including DVH sponsored 
National Hepatitis Coordinators Conference) during each budget year of 
the project period for the purpose of improving and sharing methods to 
achieve project goals and to plan, present and evaluate program 
activities.
    e. Develop and implement a plan to disseminate the findings and 
outcomes of the proposed projects, including guidelines for the 
implementation of successful integrated prevention activities, 
presentations at state-wide and national health professional meetings, 
and publication of findings and recommendations.
    2. CDC Activities:
    a. Collaborate directly in the design and implementation of studies 
and interventions to evaluate and improve delivery of recommended 
hepatitis prevention services integrated into existing programs to 
deliver prevention services.
    b. Collaborate directly in the ongoing and expanded training of 
staff in viral hepatitis.
    c. Collaborate directly in data analysis, including economic 
analysis, interpretation, and presentation and publication of project 
findings.
    d. Coordinate annual meeting of project managers or state and local 
hepatitis coordinators to plan, present, and evaluate program 
activities.
    e. Collaborate directly in the publication dissemination of 
successful findings and experiences.
    f. Assist in the development of a research protocol for 
Institutional Review Board (IRB) review by all cooperating institutions 
participating in the research project. The CDC IRB will review and 
approve the protocol initially and on at least an annual basis until 
the research project is completed.

F. Content

Letter of Intent (LOI)

    An LOI is optional for this program. The Program Announcement title 
and number must appear in the LOI. The narrative should be no more than 
two pages, double-spaced, printed on one side, with one-inch margins, 
and unreduced 12-point font. Your LOI will be used to assist CDC in 
planning for and executing the evaluation of applications submitted 
under this Program Announcement and should include the following 
information, the name of the principle investigator(s); the name, 
address, telephone, e-mail address, and fax number of the applicant's 
primary contact for writing and submitting the application; the setting 
proposed to evaluate the intervention/integration and evaluation of 
services for high risk adults and adolescents (e.g., STD clinic, HIV 
Counseling and Testing Sites (CTS), correctional health care, substance 
abuse, primary care program); a brief description of the hepatitis 
services currently available in the proposed setting; the proposed 
strategy(ies) to improve these services; and the name(s) of proposed 
collaborators (e.g., academic partners).

Applications

    Beginning October 1, 2003, applicants will be required to have a 
Dun and Bradstreet (DUNS) number to apply for a grant or cooperative 
agreement from the Federal government. The DUNS number is a nine-digit 
identification number which uniquely identifies business entities. 
Obtaining a DUNS number is easy and there is no charge.
    Although obtaining a DUNS number is not required for applications 
submitted in response to announcements with deadlines on or before 
September 30, you are encouraged to obtain a DUNS number now if you 
believe you will be submitting an application to any Federal agency on 
or after October 1, 2003. Proactively obtaining a DUNS number at the 
current time will facilitate the receipt and acceptance of applications 
after September 2003. To obtain a DUNS number, access: 
www.dunandbradstreet.com or call 1-866-705-5711.
    The Program Announcement title and number must appear in the 
application. Use the information in the Program Requirements, Other 
Requirements, and Evaluation Criteria sections to develop the 
application content. Your application will be evaluated on the criteria 
listed, so it is important to follow them in laying out your program 
plan. The narrative should be no more than 25 pages, double-spaced, 
printed on one side, with one-inch margins and unreduced 12-point font. 
The narrative should consist of a Plan, Objectives, Methods, 
Evaluation, and Budget. The program plan should address activities to 
be conducted over entire five year project period. See all attachments 
posted with this announcement on the CDC web site for more detailed 
information on development of the application content.

G. Submission and Deadline

Letter of Intent (LOI) Submission

    On or before July 24, 2003, submit the LOI to the Grants Management 
Specialist identified in the ``Where to Obtain Additional Information'' 
section of this announcement.
    CDC will host a voluntary pre-application conference call for all 
interested parties to answer any questions about this announcement or 
application process. To participate, interested parties must contact 
the program technical assistance contact within two weeks of the 
publication of the program announcement in the Federal Register.

Application Forms

    Submit the signed original and two copies of PHS form 398 (OMB 
Number 0925-0001); adhere to the instructions on the Errata Instruction 
Sheet (posted on the CDC web site) for PHS 398. Forms are available at 
the following Internet address: www.cdc.gov/od/pgo/forminfo.htm
    If you do not have access to the internet, or if you have 
difficulty accessing the forms on-line, you may contact the CDC 
Procurement and Grants Office Technical Information Management Section 
(PGO-TIM) at: 770-488-2700. Application forms can be mailed to you.

Submission Date, Time, and Address

    The application must be received by 4 p.m. Eastern Time, October 7, 
2003. Submit the application to:
    Technical Information Management--PA04009, Procurement and 
Grants Office, 2920 Brandywine Rd., Atlanta, GA 30341-4146.
    Applications may not be submitted electronically.

CDC Acknowledgment of Application Receipt

    A postcard will be mailed by PGO-TIM, notifying you that CDC has 
received your application.

Deadline

    Applications shall be considered as meeting the deadline if they 
are received before 4 p.m. Eastern Time on the deadline date. Any 
applicant who sends their application by the United States Postal 
Service or commercial delivery services must ensure that the carrier 
will be able to guarantee delivery

[[Page 40964]]

of the application by the closing date and time. If an application is 
received after closing due to (1) carrier error, when the carrier 
accepted the package with a guarantee for delivery by the closing date 
and time, or (2) significant weather delays or natural disasters, CDC 
will upon receipt of proper documentation, consider the application as 
having been received by the deadline.
    Any application that does not meet the above criteria will not be 
eligible for competition and will be discarded. The applicant will be 
notified of their failure to meet the submission requirements.

H. Evaluation Criteria

    Applicants are required to provide measures of effectiveness that 
will demonstrate the accomplishment of the various identified 
objectives of the cooperative agreement. Measures of effectiveness must 
relate to the performance goals as stated in the purpose section of 
this announcement. Measures must be objective and quantitative and must 
measure the intended outcome. These Measures of Effectiveness shall be 
submitted with the application and shall be an element of evaluation.
    An independent review group appointed by CDC will evaluate the 
application against the following criteria:
    1. Project/Research Design and Methods (45 points): The design of 
the proposal's intervention(s), activities and methods to evaluate the 
outcomes or effectiveness of their proposed intervention strategies 
will be scored as follows:
    (a) The extent to which the applicant provides Measures of 
Effectiveness that will demonstrate the accomplishment of the various 
identified objectives of the cooperative agreement. The degree to which 
the measures are objective/quantitative and adequately measure the 
intended outcome. Quality of the plan to evaluate the success 
(outcomes) of proposed strategies to improve service delivery and 
integrated services. This should include the appropriateness of the 
proposed evaluation method for the chosen intervention(s) or 
activities, the potential generalizability of the findings to other 
similar settings, and the impact of the intervention(s)/integration on 
other services being delivered at the site (e.g. HIV counseling and 
testing services). (20 points)
    The following outcome measures are of specific interest:
    (1) Changes in rate of persons seeking services in selected venues 
who truly have high risk behaviors for recommended services.
    (2) Changes in rates of STD, HIV, HCV tests accepted by persons 
recommended for testing.
    (3) Changes in rates of receipt of test results (with and without 
counseling).
    (4) Changes in rates of HIV and HCV positive persons identified, 
co-infections identified (or confirmed negative for one disease or 
both).
    (5) Changes in rates of new and chronic infections with other STDs 
(e.g., syphilis, herpes).
    (6) Changes in rates of success and follow up (which may be direct 
or by referral) for persons infected with HIV or HCV (e.g., getting 
appropriate evaluation and treatment for HIV disease, getting medical 
evaluation for evidence of chronic liver disease in persons found to be 
HCV positive, getting into substance abuse treatment, or other 
appropriate services).
    (7) Changes in rates of offering hepatitis A and hepatitis B 
vaccination to persons for whom vaccine is recommended.
    (8) Changes in rates of vaccine acceptance among these clients (and 
reasons for refusal).
    (9) Changes in rates of completion for each dose of hepatitis A and 
hepatitis B vaccine among clients recommended for and accepting 
vaccine.
    (b) Consistency with the CDC Evaluation Framework for Evaluating 
Public Health Programs (see Appendix III as posted with this 
announcement on the CDC web site) and inclusion of a clear logic model 
(or other appropriate tool) for the proposed program that clearly 
identifies process and outcome measures (indicators). (5 points)
    (c) Quality of methods to be used to evaluate the implementation of 
the interventions used in the proposed program (process evaluation). (5 
points)
    (d) Indication of how the evaluation will be used to improve 
program services. (5 points)
    (e) Indication of how evaluation will be institutionalized as a 
normative, ongoing activity. (5 points)
    (f) If research involving human subjects is proposed, the degree to 
which the applicant has met the CDC Policy requirements regarding the 
inclusion of women, ethnic, and racial groups in the proposed research. 
This includes: (1) the proposed plan for the inclusion of both sexes 
and racial and ethnic minority populations for appropriate 
representation; (2) the proposed justification when representation is 
limited or absent; (3) a statement as to whether the design of proposed 
studies is adequate to measure differences when warranted; and (4) a 
statement as to whether the plans for recruitment and outreach for 
study participants include the process of establishing partnerships 
with community/ies and recognition of mutual benefits. The extent to 
which applicant describes the existence of or plans to establish 
partnerships. (5 points)
    2. Background and Significance (30 points):
    (a) Extent to which applicant demonstrates that one or more 
hepatitis prevention activities are provided to at least five percent 
of clients seeking services in the proposed setting for whom prevention 
services are currently recommended (e.g., at least five percent of STD 
clients receive hepatitis B vaccine; at least five percent of persons 
reporting IDU past or current receive anti-HCV counseling and testing). 
(10 points)
    (b) Extent to which applicant demonstrates maximized use of 
existing resources and staff to integrate viral hepatitis prevention 
services, which clearly and appropriately addresses all ``Recipient 
Activities'' in the application; including (directly or through 
collaboration) adequately trained personnel (technical, administrative, 
and analytic), adequate facilities, research capacity including 
Institutional Review Board (IRB), adult vaccine supply (at least 
partial), and laboratory testing (at least partial) for beginning the 
project. (5 points)
    (c) Extent to which the applicant demonstrates adequate numbers of 
clients or at-risk population, (based on risk factors or other 
denominators) to achieve the objectives of the proposed evaluation or 
intervention. Projects should be of a size that represents populations 
served annually in medium to large clinics (e.g. average at least 3000/
year). (5 points)
    (d) Extent to which applicant documents experience of proposed 
personnel, either direct or collaborating, in developing, implementing, 
and evaluating strategies to improve clinical prevention services for 
high risk adults and likely has the capacity to do so for viral 
hepatitis prevention and control activities and services (e.g., 
training, testing, counseling, vaccination, clinical services). (5 
points)
    (e) Evidence of existing quality assurance mechanisms to insure 
appropriate counseling and other services as recommended for the 
proposed setting, as provided by published CDC guidelines in various 
settings (e.g. STD, HIV, Substance Abuse Treatment). (5 points)

[[Page 40965]]

3. Preliminary Studies (10 points): Quality of existing summarized data 
from proposed setting to demonstrate potential outcomes pertaining to 
the project.
    4. Specific Aims (10 points): Extent to which the applicant 
describes objectives of the proposed project which are consistent with 
the purpose and goals of this cooperative agreement program, results 
oriented, realistic, measurable and time-phased, and consistent with 
published CDC guidelines on prevention and control of hepatitis C (MMWR 
1998;47 [No. RR-19]), hepatitis B (MMWR 1991;40 [No. RR-13]) and 
hepatitis A (MMWR 1999;48 [No. RR-12]). Sexually Transmitted Diseases 
Treatment Guidelines (MMWR 2002;5 [No. RR-06]). In addition to these 
three references, additional relevant CDC guidelines that should be 
followed include those listed in Appendix II (as posted with this 
announcement on the CDC Web site).
    5. Other (5 points): Extent to which the applicant clearly 
identifies specific assigned responsibilities of all key professional 
personnel, and includes a clear time-line for activities.
    6. Human Subjects (not scored): Does the application adequately 
address the requirements of Title 45 CFR part 46 for the protection of 
human subjects? Not scored; however, an application can be disapproved 
if the research risks are sufficiently serious and protection against 
risks is so inadequate as to make the entire application unacceptable.
    7. Budget (not scored): The budget will be reviewed to determine 
the extent to which it is reasonable, clearly justified, consistent 
with the intended use of funds, and allowable.

I. Other Requirements

Technical Reporting Requirements

    Provide CDC with original plus two copies of:
    1. Interim progress report, no less than 90 days before the end of 
the budget period. The progress report will serve as your non-competing 
continuation application, and must contain the following elements:
    a. Current Budget Period Activity Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.
    d. Detailed Line-Item Budget and Justification.
    e. Additional Requested Information.
    2. Financial status report, no more than 90 days after the end of 
the budget period.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    Send all reports to the Grants Management Specialist identified in 
the ``Where to Obtain Additional Information'' section of this 
announcement.

Additional Requirements

    The following additional requirements are applicable to this 
program. For a complete description of each, see all attachments posted 
on the CDC Web site.

AR-1 Human Subjects Requirements
AR-2 Requirements for Inclusion of Women and Racial and Ethnic 
Minorities in Research
AR-4 HIV/AIDS Confidentiality Provisions
AR-6 Patient Care
AR-7 Executive Order 12372
AR-9 Paperwork Reduction Act
AR-10 Smoke Free Work Place Requirements
AR-11 Healthy People 2010
AR-12 Lobbying Restrictions
AR-15 Proof of Non-Profit Status
AR-22 Research Integrity

J. Where To Obtain Additional Information

    This and other CDC announcements, the necessary applications, and 
associated forms can be found on the CDC web site, Internet address: 
http://www.cdc.gov. Click on ``Funding'' then ``Grants and Cooperative 
Agreements.''
    For general questions about this announcement, contact: Technical 
Information Management, CDC Procurement and Grants Office, 2920 
Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.
    For business management and budget assistance in the states, 
contact: Yolanda Sledge, Grants Management Specialist, Procurement and 
Grants Office, Centers for Disease Control and Prevention, 2920 
Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2787. E-
mail Address: [email protected]
    For business management and budget assistance in the territories, 
contact: Charlotte Flitcraft, Contract Specialist, Procurement and 
Grants Office, Centers for Disease Control and Prevention, 2920 
Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2632, Email 
Address: [email protected]
    For program technical assistance, contact: Joanna Buffington, MD, 
MPH, Mailstop G-37, Division of Viral Hepatitis, Centers for Disease 
Control and Prevention, Atlanta, GA 30333, Telephone: 404-371-5293, E-
mail address: [email protected].

    Dated: July 1, 2003.
Sandra R. Manning,
Director, Procurement and Grants Office, Centers for Disease Control 
and Prevention.
[FR Doc. 03-17304 Filed 7-8-03; 8:45 am]
BILLING CODE 4163-18-P